223 related articles for article (PubMed ID: 35470692)
1. Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes.
Bellido V; Aguilera E; Cardona-Hernandez R; Diaz-Soto G; González Pérez de Villar N; Picón-César MJ; Ampudia-Blasco FJ
J Diabetes Sci Technol; 2023 Sep; 17(5):1326-1336. PubMed ID: 35470692
[TBL] [Abstract][Full Text] [Related]
2. Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control.
Yoo JH; Kim JH
Diabetes Metab J; 2020 Dec; 44(6):828-839. PubMed ID: 33389957
[TBL] [Abstract][Full Text] [Related]
3. THE ADDED AND INTERPRETATIVE VALUE OF CGM-DERIVED PARAMETERS IN TYPE 1 DIABETES DEPENDS ON THE LEVEL OF GLYCEMIC CONTROL.
Helleputte S; De Backer T; Calders P; Pauwels B; Shadid S; Lapauw B
Endocr Pract; 2021 Jan; 27(1):44-50. PubMed ID: 33475500
[TBL] [Abstract][Full Text] [Related]
4. Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C).
Martens TW; Bergenstal RM; Pearson T; Carlson AL; Scheiner G; Carlos C; Liao B; Syring K; Pollom RD
Postgrad Med; 2021 Apr; 133(3):253-264. PubMed ID: 33315495
[TBL] [Abstract][Full Text] [Related]
5. Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy.
Rodbard D
Diabetes Obes Metab; 2023 Feb; 25(2):596-601. PubMed ID: 36314133
[TBL] [Abstract][Full Text] [Related]
6. Expert Panel Recommendations for Use of Standardized Glucose Reporting System Based on Standardized Glucometrics Plus Visual Ambulatory Glucose Profile (AGP) Data in Clinical Practice.
Dagdelen S; Deyneli O; Dinccag N; Ilkova H; Osar Siva Z; Yetkin I; Yilmaz T
Front Endocrinol (Lausanne); 2021; 12():663222. PubMed ID: 35140679
[TBL] [Abstract][Full Text] [Related]
7. Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?
Bomholt T; Kofod D; Nørgaard K; Rossing P; Feldt-Rasmussen B; Hornum M
Nephron; 2023; 147(2):91-96. PubMed ID: 35830847
[TBL] [Abstract][Full Text] [Related]
8. Time-in-range for monitoring glucose control: Is it time for a change?
Bellido V; Pinés-Corrales PJ; Villar-Taibo R; Ampudia-Blasco FJ
Diabetes Res Clin Pract; 2021 Jul; 177():108917. PubMed ID: 34126129
[TBL] [Abstract][Full Text] [Related]
9. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
Front Public Health; 2022; 10():990281. PubMed ID: 36091534
[TBL] [Abstract][Full Text] [Related]
10. Clinical Recommendations for the Use of the Ambulatory Glucose Profile in Diabetes Care.
Kröger J; Reichel A; Siegmund T; Ziegler R
J Diabetes Sci Technol; 2020 May; 14(3):586-594. PubMed ID: 31718268
[TBL] [Abstract][Full Text] [Related]
11. Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus.
Kurozumi A; Okada Y; Mita T; Wakasugi S; Katakami N; Yoshii H; Kanda K; Nishida K; Mine S; Tanaka Y; Gosho M; Shimomura I; Watada H
Diabetes Res Clin Pract; 2022 Apr; 186():109836. PubMed ID: 35314256
[TBL] [Abstract][Full Text] [Related]
12. HbA
Carlson AL; Criego AB; Martens TW; Bergenstal RM
Endocrinol Metab Clin North Am; 2020 Mar; 49(1):95-107. PubMed ID: 31980124
[TBL] [Abstract][Full Text] [Related]
13. A prospective multicentre open label study to assess effect of Teneligliptin on glycemic control through parameters of time in range (TIR) Metric using continuous glucose monitoring (TOP-TIR study).
Saboo B; Erande S; Unnikrishnan AG
Diabetes Metab Syndr; 2022 Feb; 16(2):102394. PubMed ID: 35078097
[TBL] [Abstract][Full Text] [Related]
14. Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study.
Tokutsu A; Okada Y; Mita T; Torimoto K; Wakasugi S; Katakami N; Yoshii H; Uryu K; Nishida K; Arao T; Tanaka Y; Gosho M; Shimomura I; Watada H
Diabetes Obes Metab; 2022 Jan; 24(1):82-93. PubMed ID: 34498346
[TBL] [Abstract][Full Text] [Related]
15. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials.
Maiorino MI; Signoriello S; Maio A; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Giugliano D; Esposito K
Diabetes Care; 2020 May; 43(5):1146-1156. PubMed ID: 32312858
[TBL] [Abstract][Full Text] [Related]
16. Relationship of continuous glucose monitoring-related metrics with HbA1c and residual β-cell function in Japanese patients with type 1 diabetes.
Babaya N; Noso S; Hiromine Y; Taketomo Y; Niwano F; Yoshida S; Yasutake S; Kawabata Y; Ikegami H
Sci Rep; 2021 Feb; 11(1):4006. PubMed ID: 33597626
[TBL] [Abstract][Full Text] [Related]
17. Positioning time in range in diabetes management.
Advani A
Diabetologia; 2020 Feb; 63(2):242-252. PubMed ID: 31701199
[TBL] [Abstract][Full Text] [Related]
18. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes.
Vigersky RA; McMahon C
Diabetes Technol Ther; 2019 Feb; 21(2):81-85. PubMed ID: 30575414
[TBL] [Abstract][Full Text] [Related]
19. The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control.
Yoshii H; Mita T; Katakami N; Okada Y; Osonoi T; Aso K; Kurozumi A; Wakasugi S; Sato F; Ishii R; Gosho M; Shimomura I; Watada H
J Clin Endocrinol Metab; 2022 Sep; 107(10):e3990-e4003. PubMed ID: 35908248
[TBL] [Abstract][Full Text] [Related]
20. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.
Rodbard D
Diabetes Technol Ther; 2017 Jun; 19(S3):S25-S37. PubMed ID: 28585879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
